STOCK TITAN

Psyence Biomedical Ltd. Common Shares - $PBM STOCK NEWS

Welcome to our dedicated page for Psyence Biomedical Ltd. Common Shares news (Ticker: $PBM), a resource for investors and traders seeking the latest updates and insights on Psyence Biomedical Ltd. Common Shares stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Psyence Biomedical Ltd. Common Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Psyence Biomedical Ltd. Common Shares's position in the market.

Rhea-AI Summary
Psyence Biomedical (Nasdaq:PBM) announced the listing of its Phase IIb clinical trial on the Australian New Zealand Clinical Trials Registry (ANZCTR) for nature-derived psilocybin in patients with Adjustment Disorder post-cancer diagnosis. The study will test three doses in 84 patients with psychotherapy, with primary results expected in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
-
Rhea-AI Summary
Psyence Biomedical announces a partnership with Fluence and iNGENū for a Phase IIb clinical trial on psilocybin-assisted psychotherapy for Adjustment Disorder in oncology patients. The trial aims to evaluate the efficacy and safety of this therapy for patients with depression and anxiety following a cancer diagnosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
partnership clinical trial
-
Rhea-AI Summary
Psyence Biomedical welcomes a study showing nature-derived psilocybin may be more therapeutic than synthetic, with potent effects on neuroplasticity. The study, published in Molecular Psychiatry, highlights potential benefits for Palliative Care patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.2%
Tags
none
Rhea-AI Summary
Psyence Biomedical (PBM) received deficiency notifications from Nasdaq regarding its Market Value of Listed Securities (MVLS) and Market Value of Publicly Held Shares (MVPHS) being below required minimums. The company has 180 days to regain compliance by increasing its market values. Failure to comply may lead to delisting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.1%
Tags
none
-
Rhea-AI Summary
Psyence Biomedical Ltd. (Nasdaq: PBM) provides an update to shareholders following its merger with Newcourt Acquisition Corp. The company is pioneering the use of nature-derived psilocybin in mental health, focusing on Adjustment Disorder in Palliative Care. With a Phase IIb clinical trial underway in Australia, Psyence aims to lead in this emerging field.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.51%
Tags
none
-
Rhea-AI Summary
Psyence Biomedical Ltd (NASDAQ:PBM) announces approval for Phase IIb study using nature-derived psilocybin for Adjustment Disorder in palliative care patients. The study aims to improve quality of life and reduce anxiety in patients with life-limiting illnesses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.6%
Tags
Psyence Biomedical Ltd. Common Shares

Nasdaq:PBM

PBM Rankings

PBM Stock Data

13.79M
8.79M
United States of America